Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

This Little Pig-Free Product Goes To Market? Alnara's High Hopes For A PERT

This article was originally published in The Pink Sheet Daily

Executive Summary

Alnara claims its latest trial shows real-world effectiveness of liprotamase, formerly called Trizytek, and plans early 2010 NDA.
Advertisement

Related Content

Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
Lilly's Solpura Advisory Committee Could Hinge On Manufacturing Issues
Lilly's Pancreatic Enzyme Replacement Therapy Faces Advisory Committee Scrutiny
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
FDA Cites Clinical Investigator In Six Trials Of Three Cystic Fibrosis Drugs
Market Snapshot: Pancreatic Enzyme Products Get A Lift From FDA Rules
Cystic Fibrosis: Eurand Launches Zenpep, Joins Breed Of Remade Pancreatic Enzyme Products
Pancreatic Enzyme Product Activity Steps Up As NDA Deadline Approaches
Pancreatic Enzyme Product Activity Steps Up As NDA Deadline Approaches
Pancreatic Insufficiency Drug Makers Given NDA Approval Deadline Of 2008

Topics

Advertisement
UsernamePublicRestriction

Register

PS068621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel